Stem Cell Innovation for Chronic Kidney Disease: A New Paradigm by EHL BIO

New Hope for Chronic Kidney Disease Recovery

Chronic Kidney Disease (CKD) is a condition characterized by progressive decline in kidney function. Historically, the main options were limited to dialysis or kidney transplantation. However, EHL BIO has surpassed these limits by developing KDSTEM, an autologous mesenchymal stem cell therapy derived from the patient's own urine (UDSC). This method is highly distinctive as it provides non-invasive collection. Being naturally kidney-derived, these cells exhibit superior efficiency in targeting and restoring renal tissue compared to other cell types.

The treatment process focuses on utilizing the Homing Effect, where stem cells migrate to damaged areas within the kidney to initiate self-repair. This technology is internationally recognized and received the IR52 Jang Young-shil Industrial Technology Innovation Award in 2025, underscoring the advancement of EHL BIO’s high-purity cell isolation and cultivation systems aimed at enhancing patient quality of life.

Mechanism of KDSTEM and Klotho Protein

The key secret of KDSTEM lies in the expression of the Klotho protein, a protein with anti-aging properties that plays a vital role in maintaining renal homeostasis. Pre-clinical research has demonstrated that KDSTEM significantly inhibits chronic inflammation and reduces fibrosis in kidney tissue, which is the primary cause of permanent loss of kidney function.

Furthermore, urine-derived stem cells possess stable self-renewal capabilities and can effectively differentiate into specific kidney cells. Under the supervision of over 85 researchers at EHL BIO, we are committed to establishing KDSTEM as a new standard of care. It has recently received Phase 1 Clinical Trial (IND) approval from the Korean Ministry of Food and Drug Safety (MFDS) to evaluate safety and feasibility in humans, marking a global milestone in utilizing urine-derived cells for medical purposes.

KDSTEM is the world's first patented innovation using urine-derived stem cells for kidney restoration, focusing on root-cause recovery and elevating regenerative medicine standards.

GMP Production Standards and International Care

The core of treatment safety lies in the production process. EHL BIO operates modern GMP centers equipped with Class 100 Clean Rooms and HEPA Filter systems to maintain peak cleanliness. We have the capacity to cultivate up to 6,000 lots annually, ensuring patients receive consistent cell quality free from contaminants.

For CKD treatment, EHL BIO was selected as a government-funded project under the Ministry's Regenerative Medicine Technology Development program, receiving 2.567 billion KRW in support for continuous Phase 1 and 2 research. This support reflects high confidence in our technological potential to overcome the limitations of currently difficult-to-treat diseases.

Service Steps at EHL Cell Clinic

EHL Thailand is ready to facilitate patients with a clear and systematic process. It begins with an online consultation, followed by a Thai-speaking coordinator contacting you to gather information. Subsequently, expert physicians evaluate medical records to plan the journey.

Upon arrival at the EHL Cell Clinic in Apgujeong, Seoul, patients undergo a detailed health examination and cell collection (urine or fat, per plan) for high-standard laboratory cultivation. Once cells pass strict quality criteria, the treatment is administered according to the plan. Our team provides close follow-up even after the patient returns to Thailand to ensure continued well-being and quality of life.